マイクロバイオーム診断薬市場：製品タイプ、用途、エンドユーザー別-2025-2030年の世界予測

マイクロバイオーム診断薬市場は、2023年に7億9,936万米ドルと評価され、2024年には9億6,027万米ドルに達すると予測され、CAGR 20.72%で成長し、2030年には29億8,787万米ドルに達すると予測されています。

マイクロバイオーム診断薬は、ヒトや他の宿主の微生物群集の遺伝物質を分析して健康状態を診断し、個別化医療に革命をもたらすことに焦点を当てています。この市場の必要性は、マイクロバイオームが健康や疾病において果たす役割が認識されつつあることに起因しており、マイクロバイオームは消化器疾患、代謝疾患、免疫疾患などの分野における早期発見、モニタリング、治療の個別化を支援します。その用途はヘルスケア、医薬品、農業、バイオテクノロジーに及び、最終用途は病院、診断ラボ、研究機関、専門クリニックです。市場開拓の原動力となっているのは、研究開発活動の活発化、慢性疾患の有病率の上昇、マイクロバイオームが健康に果たす重要な役割に対する意識の高まりです。政府による投資や学術機関とバイオテクノロジー企業との提携が、さらに進歩を後押ししています。しかし、市場は、高い検査コスト、倫理的配慮、規制上のハードル、データプライバシーに関する懸念などの課題に直面しており、これが成長を阻害する可能性があります。複雑な微生物と宿主の相互作用の理解や、研究の臨床への応用には限界があり、さらなる課題となっています。こうしたハードルにもかかわらず、精密医療におけるマイクロバイオーム診断薬の適用拡大、非侵襲的検査法の開発、データ解析のための人工知能の統合には大きな機会が存在します。企業は、ヘルスケア・インフラが整備されつつあり、医療ニーズが満たされていない未開拓の地域を開拓することができます。費用対効果の高い迅速診断ツールの開発でイノベーションを起こし、消費者啓蒙キャンペーンを重視することで、市場の受容拡大を促進できると思われます。市場は本質的にダイナミックであり、急速な技術進歩や、活発な新興企業や既存企業による競合情勢が顕著です。企業は共同研究、マルチオミクス・アプローチ、包括的マイクロバイオーム・プロファイリング・サービスの提供に注力することで成功を収めることができます。急速に進化するこの分野では、戦略的パートナーシップや画期的な技術を活用するための機敏さと警戒が求められています。

市場力学：急速に進化するマイクロバイオーム診断薬市場の主要市場インサイトを公開

マイクロバイオーム診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の有病率の上昇とマイクロバイオーム診断薬の重要性
  • マイクロバイオーム研究に対する政府の取り組みと支援
• 市場抑制要因
  • マイクロバイオーム診断薬に対する償還政策の欠如
• 市場機会
  • マイクロバイオーム研究への投資の増加
  • 個別化治療の開発におけるマイクロバイオーム診断薬の可能性の高まり
• 市場の課題
  • マイクロバイオームをターゲットとした標準化されたプロトコルと利用可能な治療薬の欠如

ポーターのファイブフォース：マイクロバイオーム診断薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：マイクロバイオーム診断薬市場における外部からの影響の把握

外部マクロ環境要因は、マイクロバイオーム診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析マイクロバイオーム診断薬市場における競合情勢の把握

マイクロバイオーム診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスマイクロバイオーム診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、マイクロバイオーム診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨マイクロバイオーム診断薬市場における成功への道筋を描く

マイクロバイオーム診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の有病率の上昇とマイクロバイオームに基づく診断の重要性
    • マイクロバイオーム調査に対する政府の取り組みと支援
  • 抑制要因
    • マイクロバイオームに基づく診断に対する償還ポリシーの欠如
  • 機会
    • マイクロバイオームに基づく調査への投資増加
    • パーソナライズされた治療法の開発におけるマイクロバイオーム診断薬の潜在能力の高まり
  • 課題
    • マイクロバイオームをターゲットとした標準化されたプロトコルと利用可能な治療法の欠如
• 市場セグメンテーション分析
  • 製品タイプ：複雑な分析に対応できる正確で効率的な機器の必要性
  • エンドユーザー：製薬企業やバイオテクノロジー企業におけるパーソナライズされた治療法の開発のためのマイクロバイオーム診断薬の採用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 マイクロバイオーム診断薬市場：製品タイプ別

• 機器
• 試薬とキット

第7章 マイクロバイオーム診断薬市場：用途別

• 胃腸障害
• 感染症
• 代謝障害

第8章 マイクロバイオーム診断薬市場：エンドユーザー別

• 製薬・バイオテクノロジー企業
• 調査・学術機関

第9章 南北アメリカのマイクロバイオーム診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のマイクロバイオーム診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのマイクロバイオーム診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 健康と病気のための経路ベースのマイクロバイオームプロファイリングサービス「ターゲットマイクロバイオームプロファイリング」を開始
  • 膣マイクロバイオームに焦点を当てた精密な女性向け健康スタートアップEvvyが1,400万米ドルのシリーズA資金調達を発表
  • XumeはMicrobiome.inおよびTruDiagnoと提携し、人々が腸内細菌叢に基づいた選択を行えるよう支援します。
• 戦略分析と提言

企業一覧

• 4D Pharma PLC
• AOBiome Therapeutics
• Atlas Biomed
• BioGaia
• BIOHM Health
• Bione Ventures Private Limited
• DayTwo
• DNA Genotek Inc. by OraSure Technologies Inc.
• Du Pont De Nemours and Co.
• Enterome
• Evvy
• Ferring Pharmaceuticals
• Finch Therapeutics Group
• Flightpath Biosciences, Inc.
• Genetic Analysis AS
• Gnubiotics Sciences
• International Flavors & Fragrances Inc
• Luxia Scientific
• MEtabiomics
• Microba Life Sciences
• OptiBiotix Health PLC
• Osel Inc.
• Quantbiome, Inc.
• Rebiotix
• Second Genome, Inc.
• Seed Health
• Seres Therapeutics
• Sun Genomics
• Symbiotix Biotherapies,
• Synlogic, Inc.
• Synthetic Biologics
• Vedanta Biosciences, Inc.
• Viome Life Sciences, Inc.
• ViThera
• ViThera Pharmaceuticals, Inc.
• Yakult Honsha Co.
• YSOPIA Bioscience

LIST OF FIGURES

• FIGURE 1. MICROBIOME DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. MICROBIOME DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. MICROBIOME DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. MICROBIOME DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MICROBIOME DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MICROBIOME DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. CANADA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 28. CANADA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. CANADA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. INDIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. INDIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. INDIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ITALY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ITALY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ITALY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. POLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. POLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. POLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. QATAR MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. QATAR MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. QATAR MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. MICROBIOME DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 145. MICROBIOME DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Microbiome Diagnostics Market was valued at USD 799.36 million in 2023, expected to reach USD 960.27 million in 2024, and is projected to grow at a CAGR of 20.72%, to USD 2,987.87 million by 2030.

Microbiome diagnostics focuses on analyzing the genetic material of microbial communities in human and other hosts to diagnose health conditions, offering a revolution in personalized medicine. This market's necessity stems from the growing recognition of the microbiome's role in health and disease, where it aids in early detection, monitoring, and treatment personalization in areas like gastrointestinal, metabolic, and immune disorders. Its applications span healthcare, pharmaceuticals, agriculture, and biotechnology, with end-uses in hospitals, diagnostic labs, research institutions, and specialty clinics. Market growth is driven by increasing research and development activities, the rising prevalence of chronic diseases, and growing awareness of the microbiome's critical health roles. Government investments and collaborations between academic institutions and biotech companies further bolster advancements. However, the market faces challenges such as high testing costs, ethical considerations, regulatory hurdles, and data privacy concerns that may impede growth. Limitations in understanding the complex microbiome-host interactions and translating research into clinical practice pose additional challenges. Despite these hurdles, substantial opportunities exist in expanding the application of microbiome diagnostics in precision medicine, developing non-invasive testing methods, and integrating artificial intelligence for data analysis. Companies can tap into unexplored regions with rising healthcare infrastructure and unmet medical needs. Innovating in developing cost-effective, rapid diagnostic tools and emphasizing consumer awareness campaigns could drive wider market acceptance. The market is inherently dynamic, marked by rapid technological advancements and a competitive landscape with active start-ups and established players. Businesses can succeed by focusing on collaborative research, multi-omic approaches, and offering comprehensive microbiome profiling services. This rapidly evolving sector demands agility and vigilance to capitalize on aimed strategic partnerships and breakthrough technologies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Microbiome Diagnostics Market

The Microbiome Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of chronic diseases and significance of microbiome-based diagnostics
  • Government initiatives and support for microbiome research
• Market Restraints
  • Lack of reimbursement policies for microbiome-based diagnostics
• Market Opportunities
  • Increasing investment in microbiome-based research
  • Growing potential of microbiome diagnostics in developing personalized treatments
• Market Challenges
  • Lack of standardized protocols and available therapeutics targeting the microbiome

Porter's Five Forces: A Strategic Tool for Navigating the Microbiome Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Microbiome Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Microbiome Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Microbiome Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Microbiome Diagnostics Market

A detailed market share analysis in the Microbiome Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Microbiome Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Microbiome Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Microbiome Diagnostics Market

A strategic analysis of the Microbiome Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Microbiome Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Pharma PLC, AOBiome Therapeutics, Atlas Biomed, BioGaia, BIOHM Health, Bione Ventures Private Limited, DayTwo, DNA Genotek Inc. by OraSure Technologies Inc., Du Pont De Nemours and Co., Enterome, Evvy, Ferring Pharmaceuticals, Finch Therapeutics Group, Flightpath Biosciences, Inc., Genetic Analysis AS, Gnubiotics Sciences, International Flavors & Fragrances Inc, Luxia Scientific, MEtabiomics, Microba Life Sciences, OptiBiotix Health PLC, Osel Inc., Quantbiome, Inc., Rebiotix, Second Genome, Inc., Seed Health, Seres Therapeutics, Sun Genomics, Symbiotix Biotherapies,, Synlogic, Inc., Synthetic Biologics, Vedanta Biosciences, Inc., Viome Life Sciences, Inc., ViThera, ViThera Pharmaceuticals, Inc., Yakult Honsha Co., and YSOPIA Bioscience.

Market Segmentation & Coverage

This research report categorizes the Microbiome Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Instruments and Reagents & Kits.
• Based on Application, market is studied across Gastrointestinal Disorders, Infectious Diseases, and Metabolic Disorders.
• Based on End-user, market is studied across Pharmaceutical & Biotechnology Companies and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic diseases and significance of microbiome-based diagnostics
    • 5.1.1.2. Government initiatives and support for microbiome research
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of reimbursement policies for microbiome-based diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investment in microbiome-based research
    • 5.1.3.2. Growing potential of microbiome diagnostics in developing personalized treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of standardized protocols and available therapeutics targeting the microbiome
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Need for accurate and efficient instruments capable of handling complex analyses
  • 5.2.2. End-user: Growing adoption of microbiome diagnostics in pharmaceutical and biotechnology companies to develop personalized therapies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Microbiome Diagnostics Market, by Product Type

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents & Kits

7. Microbiome Diagnostics Market, by Application

• 7.1. Introduction
• 7.2. Gastrointestinal Disorders
• 7.3. Infectious Diseases
• 7.4. Metabolic Disorders

8. Microbiome Diagnostics Market, by End-user

• 8.1. Introduction
• 8.2. Pharmaceutical & Biotechnology Companies
• 8.3. Research & Academic Institutes

9. Americas Microbiome Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Microbiome Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Microbiome Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Launch of "Targeted Microbiome Profiling", a pathway-based microbiome profiling service for health and disease
  • 12.3.2. Evvy, Precision Women's Health Startup focused on the Vaginal Microbiome, Announces USD 14 million Series A
  • 12.3.3. Xume partners with Microbiome.in and TruDiagno to help people make gut microbiome-informed choices
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 4D Pharma PLC
• 2. AOBiome Therapeutics
• 3. Atlas Biomed
• 4. BioGaia
• 5. BIOHM Health
• 6. Bione Ventures Private Limited
• 7. DayTwo
• 8. DNA Genotek Inc. by OraSure Technologies Inc.
• 9. Du Pont De Nemours and Co.
• 10. Enterome
• 11. Evvy
• 12. Ferring Pharmaceuticals
• 13. Finch Therapeutics Group
• 14. Flightpath Biosciences, Inc.
• 15. Genetic Analysis AS
• 16. Gnubiotics Sciences
• 17. International Flavors & Fragrances Inc
• 18. Luxia Scientific
• 19. MEtabiomics
• 20. Microba Life Sciences
• 21. OptiBiotix Health PLC
• 22. Osel Inc.
• 23. Quantbiome, Inc.
• 24. Rebiotix
• 25. Second Genome, Inc.
• 26. Seed Health
• 27. Seres Therapeutics
• 28. Sun Genomics
• 29. Symbiotix Biotherapies,
• 30. Synlogic, Inc.
• 31. Synthetic Biologics
• 32. Vedanta Biosciences, Inc.
• 33. Viome Life Sciences, Inc.
• 34. ViThera
• 35. ViThera Pharmaceuticals, Inc.
• 36. Yakult Honsha Co.
• 37. YSOPIA Bioscience